Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-659 + NKTR-214 in Advanced Non-Hodgkin Lymphoma
NCT03772288Phase 1Withdrawn
- Sponsor
- Calithera Biosciences
- Start
- Apr 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of mivavotinib in B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 2 more (2 arms), sponsored by Calithera Biosciences. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose. Planned start Apr 2019; status: withdrawn.
02
Drugs
mivavotinib
03
Conditions
B-cell non-Hodgkin lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone lymphoma (MZL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03772288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03772288.